首页> 外文期刊>Antimicrobial agents and chemotherapy. >Pharmacokinetics and Dialytic Clearance of Isavuconazole during In Vitro and In Vivo Continuous Renal Replacement Therapy
【24h】

Pharmacokinetics and Dialytic Clearance of Isavuconazole during In Vitro and In Vivo Continuous Renal Replacement Therapy

机译:体外和体内体内异戊酰唑的药代动力学和透析清除

获取原文
获取原文并翻译 | 示例
           

摘要

The pharmacokinetics (PK) and dialytic clearance of isavuconazole in vitro and in 7 solid-organ transplant patients undergoing continuous renal replacement therapy (CRRT) were evaluated. In vivo, the mean (+/- standard deviation [SD]) plasma PK parameters of isavuconazole were as follows: maximum concentration of drug in serum (C-max), 4.00 +/- 1.45 mg/liter; minimum concentration of drug in serum (C-min), 1.76 +/- 0.76 mg/liter; half-life (t(1/2)), 48.36 +/- 29.78 h; volume of distribution at steady state (V-ss), 288.78 +/- 182.11 liters, clearance at steady state (CLss), 4.85 +/- 3.79 liters/h; and area under the concentration-time curve (AUC), 54.01 +/- 20.98 mg . h/liter. Transmembrane clearance represented just 0.7% of the total isavuconazole clearance. These data suggest that isavuconazole is not readily removed by CRRT and no dose adjustments are necessary.
机译:评价药代动力学(PK)和体外异戊酰唑的透析性清除,在经历连续肾置换疗法(CRRT)的7个固体器官移植患者中进行了评估。 在体内,异戊酰唑的平均值(+/-标准偏差[SD])等离子体PK参数如下:血清中最大浓度(C-MAX),4.00 +/- 1.45 mg /升; 血清中药物的最小浓度(C-min),1.76 +/- 0.76 mg /升; 半衰期(T(1/2)),48.36 +/- 29.78小时; 稳态(V-SS)的分布量,288.78 +/- 182.11升,稳态(CLSS)的间隙,4.85 +/- 3.79升/小时; 和浓度 - 时间曲线(AUC),54.01 +/- 20.98毫克的区域。 H /升。 跨膜间隙仅占总产能清除率的0.7%。 这些数据表明,CRRT不容易去除异戊基唑,并且没有必要调整。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号